Skip to content

Suprapubic Single-incision Laparoscopic Appendectomy Versus Conventional Appendectomy: a Randomized Controlled Trial

Suprapubic Single-incision Laparoscopic Appendectomy Versus Conventional Multiport Appendectomy: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02499016
Enrollment
208
Registered
2015-07-15
Start date
2015-06-30
Completion date
2018-12-31
Last updated
2015-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications

Keywords

Appendicitis, Appendectomy, Single-incision

Brief summary

Conventional laparoscopic appendectomy(CLA) is the current standard treatment. To obtain additional benefits such as a better cosmetic outcome, the investigators developed a surgical option termed suprapubic single-incision laparoscopic appendectomy (SSILA), which creates a non-visible scar, that was preliminarily shown to be feasible and safe in our previous retrospective studies To further evaluate the feasibility, safety and cosmetic results of this innovative approach, the investigators compared the outcomes of SSILA and CLA by performing a randomized controlled trial.

Interventions

PROCEDUREsuprapubic single-incision laparoscopic appendectomy

the approach of appendectomy

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* acute appendicitis or interval appendicitis * informed consent

Exclusion criteria

* diagnosis of appendicitis was not clinically established (symptoms attributable to urinary or gynecological problems) * history of cirrhosis and coagulation disorders * suspected or proven malignancy * contraindication to general anesthesia (severe cardiac and/or pulmonary disease) * inability to give informed consent(severe mental disease) * pregnancy * BMI\>30kg/m2 * generalized peritonitis

Design outcomes

Primary

MeasureTime frameDescription
incidence of complications30 daysThe early morbidity rate is defined as the event observed during operation and within 30 days after surgery

Secondary

MeasureTime frameDescription
mortality rate30 days
cosmetic results30 daysCosmetic assessment is perform using body image scale and cosmetic scale.
operative timeintraoperative
time to recover14 days
Pain score14 daysPostoperative pain is recorded using the visual analog scale (VAS) pain score tool on postoperative day 1, 2, 3 and the day of discharge.

Countries

China

Contacts

Primary ContactGuoxin Li, M.D.,Ph. D.
gzliguoxin@163.com+86-138-0277-1450
Backup ContactYanan Wang, M.D
wyn8116@163.com+86-150-1875-3181

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026